Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
…, HE Al Romaihi, AA Butt, MH Al-Thani… - … England Journal of …, 2021 - Mass Medical Soc
Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The …
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The …
Protection against the Omicron variant from previous SARS-CoV-2 infection
…, AA Butt, HE Al-Romaihi, MH Al-Thani… - … England Journal of …, 2022 - Mass Medical Soc
… Mohamed H. Al-Thani, MD … Weill Cornell Medicine–Qatar ; the Qatar Ministry of Public
Health; Hamad Medical Corporation; and Sidra Medicine . The Qatar Genome Program and Qatar …
Health; Hamad Medical Corporation; and Sidra Medicine . The Qatar Genome Program and Qatar …
Effects of previous infection and vaccination on symptomatic omicron infections
…, AA Butt, HE Al-Romaihi, MH Al-Thani… - … England Journal of …, 2022 - Mass Medical Soc
Background The protection conferred by natural immunity, vaccination, and both against
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the …
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the …
Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar
…, AA Butt, HE Al-Romaihi, MH Al-Thani… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19)
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …
mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar
…, MG Al Kuwari, HE Al Romaihi, MH Al-Thani… - Nature medicine, 2021 - nature.com
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar
…, AA Butt, HE Al-Romaihi, MH Al-Thani… - Nature …, 2022 - nature.com
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted
a matched, test-negative, case-control study to estimate duration of protection of the second …
a matched, test-negative, case-control study to estimate duration of protection of the second …
Protective effect of previous SARS-CoV-2 infection against Omicron BA. 4 and BA. 5 subvariants
…, AA Butt, HE Al-Romaihi, MH Al-Thani… - … England Journal of …, 2022 - Mass Medical Soc
… Mohamed H. Al-Thani, MD … Supported by the Biomedical Research Program and the
Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar; …
Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar; …
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
…, MG Al Kuwari, HE Al Romaihi, AA Butt, MH Al-Thani… - Nature medicine, 2021 - nature.com
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant,
we conducted a matched test-negative case–control study to assess the real-world …
we conducted a matched test-negative case–control study to assess the real-world …
Immune imprinting and protection against repeat reinfection with SARS-CoV-2
…, AA Butt, HE Al-Romaihi, MH Al-Thani… - … England Journal of …, 2022 - Mass Medical Soc
… Mohamed H. Al-Thani, MD … Supported by the Biomedical Research Program and the
Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar …
Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar …
[HTML][HTML] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
…, MG Al Kuwari, HE Al Romaihi, MH Al-Thani… - …, 2021 - thelancet.com
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …